DA-CAN CHEN

D&C Biopharm is a clinical-stage biotechnology company specializing in the development of next-generation mRNA therapeutics and vaccines. Founded by Dr. Da-Can Chen, a former senior scientist at Genentech and an expert in lipid nanoparticle (LNP) delivery, the company leverages its proprietary delivery platforms to target oncology and infectious diseases. D&C Biopharm is an affiliate of D&C Biology (Deyun Kangrui), a leader in spatial omics and single-cell sequencing, which allows for the integration of multi-omics data into drug discovery. The company's pipeline includes personalized neoantigen-based mRNA cancer vaccines and off-the-shelf mRNA therapeutics designed to overcome the limitations of traditional drug delivery. Headquartered in Suzhou, China, D&C Biopharm is backed by prominent investors including IDG Capital and Matrix Partners China.